07:55:21 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-11-09 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-23 Årsstämma 2023
2023-05-19 Kvartalsrapport 2023-Q1
2023-02-27 Bokslutskommuniké 2022
2023-01-09 Extra Bolagsstämma 2022
2022-11-01 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning DICOT 0.00 SEK
2022-05-24 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-28 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-10-06 Extra Bolagsstämma 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-26 Ordinarie utdelning DICOT 0.00 SEK
2021-05-25 Årsstämma 2021
2021-05-17 Kvartalsrapport 2021-Q1
2021-02-24 Bokslutskommuniké 2020
2020-11-23 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning DICOT 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-15 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-28 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-08-22 Extra Bolagsstämma 2019
2019-05-17 Ordinarie utdelning DICOT 0.00 SEK
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-16 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriLäkemedel & Handel
Dicot utvecklar läkemedel för behandling av sexuella dysfunktioner, i huvudsak erektionsproblem hos män. Läkemedelskandidaten LIB-01 består av en molekyl som är en halvsyntetisk version av en aktiv substans från naturen. Dicots strategi är att utveckla LIB-01 fram till kliniska fas 2-studier och söka partnerskap med internationella läkemedelsbolag för att därefter ta preparatet till ett registrerat läkemedel. Bolaget grundades 2015 och har sitt huvudkontor i Uppsala.
2022-03-17 12:00:00

Press release: Uppsala, March 17, 2022. The demand for potency drugs has increased by 41% in the last three years, according to statistics from IQVIA. Despite this, drugs available today do not manage to treat everyone in need. For example, up to 30-40% do not respond properly. The Swedish pharmaceutical company Dicot is developing a new type of potency drug to address this need.

Despite the fact that the demand for potency drugs is rising, there are deficiencies among those present on the market today and who were introduced twenty years ago. Between 30 and 40 percent of patients do not respond well to treatment. In addition, many men experience side effects such as headaches, abdominal pain, digestive problems and visual disturbances, hence leading to many choosing to stop treatment. Another challenge is the short duration of effect, maximum 36 hours.

Common to all existing drugs is that they are fully synthetic so-called PDE-5 inhibitors which make it easier for the blood vessels in the penis to dilate. However, at the same time PDE-5 inhibitors also affect blood vessels in other parts of the body causing unwanted problems. The pharmaceutical company Dicot is developing a new type of potency drug that has an organic origin and is a semi-synthetic substance aimed at improving the performance of erectile dysfunction drugs.

- Addressing the challenges of today's PDE-5 inhibitors is crucial in the development of our drug candidate LIB-01, which, among other things, has a duration of effect of over seven days according to results from animal studies. To confirm future clinical needs, we have commissioned a series of interviews with leading sexual medicine physicians. They verify the need for better alternatives and stress that a drug with fewer side effects and longer duration of effect is paramount. Dr Chris McMahon, former chairman of The International Society of Sexual Medicine, says that "one tablet a week with proven effect, proven safety profile and no significant side effects, would be a game changer". Professor Arthur Burnett, urologist at the John Hopkins School of Medicine in Baltimore, states that "LIB-01 can replace PDE-5 inhibitors if the long duration of effect at low dose can be proven," something we did in the last animal studies 2021, says Göran Beijer, CEO of Dicot.

For further information, please contact:

Göran Beijer CEO

Tel: +46 706 63 60 09

Email: goran.beijer@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.